 Their application may be beneficial in patients with hyperfibrinolysis because they arrest bleeding rapidly if the other components of the haemostatic system are not severely affected.This may help to avoid the use of blood products such as fresh frozen plasma (FFP) with its associated risks of infections or anaphylactic reactions.In 2010, the CRASH-2 trial showed that the antifibrinolytic drug tranexamic acid safely reduces mortality in bleeding trauma patients.